Please login to the form below

Not currently logged in
Email:
Password:

cell therapy

This page shows the latest cell therapy news and features for those working in and with pharma, biotech and healthcare.

FDA delays review of Novartis’ MS drug ofatumumab

FDA delays review of Novartis’ MS drug ofatumumab

Regulator now expected to deliver verdict on application in September. The FDA has extended its review time for Novartis’ multiple sclerosis therapy ofatumumab, delaying a possible launch of a drug the ... Ofatumumab has a chance of becoming the first

Latest news

  • BMS suspends new clinical trials as COVID-19 cases rise in US BMS suspends new clinical trials as COVID-19 cases rise in US

    It has also suspended screening, enrolment and apheresis in its cell therapy trials. ... That decision won’t however affect its two most advanced clinical programmes – idecabtagene vicleucel (ide-cel or bb2121) for multiple myeloma and B-cell

  • Keytruda hits primary endpoint in confirmatory lymphoma trial Keytruda hits primary endpoint in confirmatory lymphoma trial

    It was the first green light for the drug in a haematological cancer, and Keytruda has since gone on to receive approval in primary mediastinal B-cell lymphoma, a rare form ... Keytruda’s main growth indication is undoubtedly non-small cell lung cancer,

  • Gilead swoops on Forty Seven with $4.9bn all-cash deal Gilead swoops on Forty Seven with $4.9bn all-cash deal

    a run of M&A that hit a peak in 2017 with Gilead’s $11.9bn acquisition of CAR-T cell therapy player Kite Pharma. ... Magrolimab complements our existing work in haematology, adding a non-cell therapy programme that complements Kite’s pipeline of cell

  • IMV preps pivotal trials for ovarian cancer T cell therapy IMV preps pivotal trials for ovarian cancer T cell therapy

    It said the results were impressive given that the patients were a very hard-to-treat group, having received at least three prior lines of therapy. ... HC Wainwright analyst Jospeh Pantginis has a different take however, calling the data “quite

  • GSK pays $50m upfront to tap Immatics’ cell therapy platform GSK pays $50m upfront to tap Immatics’ cell therapy platform

    TCR therapies are emerging as a new type of cell therapy that involves re-engineering T cells so they are better at binding to and destroying cancer cells. ... GSK is just the latest in a series of drugmakers to cut deals with Immatics for access to its

More from news
Approximately 9 fully matching, plus 299 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    CD19 is a target ubiquitously expressed in a number of B-cell malignancies. ... Liso-cel can potentially be the best-in-class anti-CD19 based on its differentiated profile compared with other cell therapies: the therapy is manufactured in a defined 1:1

  • China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

    Government policy amendments have accelerated the regulatory pathway, which is important as cell therapy had been a controversial area,” added Xiaofeng, who was born in China and has a PhD in ... There was no robust, regulatory control but that has

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... knocked back by an FDA

  • Rethinking trials: the pros and cons of protocol amendments Rethinking trials: the pros and cons of protocol amendments

    Product complexity. The drug industry’s evolution from a provider of chemical-based medicine into a developer of larger molecule drugs and cell and gene therapies is likely to result in ... For example, in the case of a failing lot of autologous cell

  • Delivering the promise of regenerative medicine Delivering the promise of regenerative medicine

    The Cell and Gene Therapy Catapult is also continuing to work to bridge the gap between ‘translational’ research and commercialisation. ... to cell and tissue requirements.

More from intelligence
Approximately 0 fully matching, plus 46 partially matching documents found.

Latest appointments

  • Health comms agency emotive hires new cell and gene therapy leader Health comms agency emotive hires new cell and gene therapy leader

    Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where

  • Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult and more

    Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Zelluna Immunotherapy appoints chief technology officer Zelluna Immunotherapy appoints chief technology officer

    Arjan Roozen, who previously headed up the GMP solutions and manufacturing team at French cell therapy group Cellectis, comes with expertise in microbiology and molecular microbiology. ... Miguel Forte, chief executive officer of Zelluna, said:

More from appointments
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 18 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics